Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer
Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the combination of docetaxel and
carboplatin is an effective treatment for patients with triple negative breast cancer.